Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Altimmune, Inc. logo

Altimmune, Inc. (ALT) Stock Ticker

NASDAQ: ALT · Healthcare · Biotechnology
$3.06+0.66%
USD · as of 2026-09-28 · market cap $595.1M
Open ALT in TickrDownload for iPhone

ALT right now

28% of the float is sold short.
Options expect by Oct 6±9.1%
Options expect by Oct 29±18.9%
Priced in for Nov 5 earnings±20.9%
IV rank (30-day)4% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full ALT picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on ALT
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

ALT stock facts

Ticker symbolALT
ExchangeNASDAQ Global Market
SectorHealthcare
IndustryBiotechnology
Market cap$595.1M
CEOJerome Benedict Durso
Employees57
HeadquartersGaithersburg, MD, US
IPO date2017-05-26
Websitealtimmune.com

What you can see for ALT on Tickr

Live ALT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ALT report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Altimmune, Inc.?

The ticker symbol for Altimmune, Inc. is ALT, listed on the NASDAQ Global Market.

What is ALT?

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and…

HomeExploreMarketLists
All pages